School of Psychology, University of East London, Water Lane, Stratford, LondonE15 4LZ, UK.
Epidemiol Psychiatr Sci. 2022 Feb 15;31:e13. doi: 10.1017/S2045796021000846.
It is estimated that electroconvulsive therapy is still administered to approximately a million people a year. It involves passing enough electric current through the human brain, eight to twelve times, to cause convulsions, in the hope of somehow alleviating emotional suffering, primarily depression. There have only ever been 11 placebo-controlled studies (where general anaesthesia is administered but the electric shock is withheld), all of which were pre-1986, had very small sample sizes and were seriously methodologically flawed. Five of these studies found no difference between the two groups at the end of treatment, four found ECT produced better outcomes for some patients, and two produced mixed results, including one where psychiatrists' ratings produced a difference, but the ratings of nurses and patients did not. In the 80 years since the first ECT no studies have found any evidence that ECT is better than placebo beyond the end of treatment. Nevertheless, all five meta-analyses relying on these studies have somehow concluded that ECT is more effective than placebo despite the studies' multiple failings. Meanwhile, evidence of persistent or permanent memory loss in 12% to 55% of patients has accumulated. Attempts to highlight this failure of ECT proponents to provide robust evidence that their treatment is effective and safe are routinely dismissed, diminished, denied and denounced. This paper responds to one such attempt, by Drs Meechan, Laws, Young, McLoughlin and Jauhar, to discredit two systematic reviews of the eleven pre-1986 studies, in 2010 and 2019, the latter of which also reviewed five meta-analyses that had ignored the studies' failings. The criticisms and claims of the recent crtiique of the two systematic reviews are examined in detail, by the first author of both reviews, for accuracy, relevance and logic. The critique is found to include multiple errors, misrepresentations, omissions, inconsistencies and logical flaws. It is concluded that Meechan et al. fail to make a fact-based, coherent argument against suspending ECT pending a series of large, carefully designed placebo-controlled studies to establish whether ECT does have any beneficial effects against which to weigh the significant established adverse effects.
据估计,每年仍有大约 100 万人接受电休克疗法。这种疗法涉及通过人脑传递足够的电流,使其抽搐 8 到 12 次,以期以某种方式缓解情绪痛苦,主要是抑郁症。只有 11 项安慰剂对照研究(给予全身麻醉但不给予电击),所有这些研究都是在 1986 年之前进行的,样本量非常小,并且存在严重的方法学缺陷。其中 5 项研究在治疗结束时发现两组之间没有差异,4 项研究发现电休克对某些患者有更好的效果,2 项研究结果混杂,包括一项研究中精神病医生的评分存在差异,但护士和患者的评分没有差异。自首次电休克治疗 80 年来,没有任何研究发现电休克在治疗结束后比安慰剂有任何证据表明其更有效。然而,所有五项依赖这些研究的荟萃分析都以某种方式得出结论,认为电休克比安慰剂更有效,尽管这些研究存在多种缺陷。与此同时,12%至 55%的患者出现持续性或永久性记忆丧失的证据不断积累。试图强调电休克支持者未能提供有力证据证明其治疗有效且安全的这种失败的尝试,通常被驳回、贬低、否认和谴责。本文回应了 Meechan 博士、Laws 博士、Young 博士、McLoughlin 博士和 Jauhar 博士的一次此类尝试,他们试图诋毁 2010 年和 2019 年对 11 项 1986 年前研究的两项系统评价,后者还对五项忽视研究缺陷的荟萃分析进行了审查。这两篇综述的第一作者详细检查了最近对这两项系统评价的批评的批评和主张,以评估其准确性、相关性和逻辑性。研究发现,这些批评存在多个错误、错误陈述、遗漏、不一致和逻辑缺陷。结论是,Meechan 等人未能提出一个基于事实、连贯的论点,反对暂停电休克治疗,直到进行一系列大型、精心设计的安慰剂对照研究,以确定电休克是否确实有任何有益的效果,可以权衡其显著的已知不良影响。